Diligence memo · auto-generated · as of July 2, 2026
Augmenix Inc
Augmenix Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Augmenix Inc operates in Biotechnology, based in WALTHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Augmenix Inc has raised $41M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2011-05-11.
Most recent recorded round closed around 2016-07-07.
Valuation (modeled)modeled
Provath models Augmenix Inc at approximately $217M (range $6.5M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.03× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 79% of Biotechnology peers (4293 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.